Pages

Wednesday, June 13, 2007

RNAi by single-stranded RNAs

Before RNAi, there was antisense. Antisense strategies typically aim to suppress gene expression by either preventing translation initiation or degrading the messenger mRNA through an RNase H mechanism. As more mechanistic insight into the RNAi pathway was gained, it became clear that the final active, so called “guide” RNA that recognises and causes cleavage of the target RNA by RNAi is a single-stranded 19-23nt RNA bound to the catalytic RiSC endonuclease Argonaute 2 (in humans).

Sure enough, the provision of single-stranded RNAs was then shown by the Tuschl lab to be sufficient for inducing RNAi (Martinez et. al., 2002), although considerably higher concentrations were needed compared to the conventional double-stranded siRNAs in vitro. This work and potential applications thereof are the subject of a USPTO patent application by the Max Planck Society.

Nevertheless, ISIS Pharmaceuticals would claim that its antisense patents cover any therapy making use of a single-strand antisense mechanism, and in their interpretation this includes RNAi with single-stranded RNAs. ISIS’ leadership in nucleic acid technology such as nucleic acid modification and manufacturing technology is without doubt. This is also the reason why Alnylam, the leading RNAi company (of which Tuschl is a co-founder), has taken an exclusive license to a number of ISIS’ patents for the development of RNAi therapeutics, particularly for the use of modified siRNAs.

Although in tissue culture it is clear that double-stranded siRNAs are much more potent inducers of RNAi than single-stranded small RNAs, single-stranded RNAi molecules may have some utility for in vivo applications. In addition to the potential cost of goods advantage of a single-stranded versus a double-stranded approach, the delivery of single-strand RNA-like molecules to organs such as the liver may not even require as much as a formulation into a special delivery composition, as is suggested by the ability of single-stranded antisense compounds such as ISIS’ ApoB100-targeting 301012 to enter liver cells following subcutaneous injection. It is also possible, although not proven, that some of ISIS’ antisense compounds, particularly those with limited 5’ modifications, actually work through an RNAi mechanism.

The issue therefore relates to the value of a claim to a mechanism that was not even known to exist at the time when ISIS applied for patents relating to RNase-mediated gene suppression by an antisense mechanism involving ANY RNAse activity. While I think it is almost impossible that these claims will supersede the fundamental Fire-Mello and Tuschl II RNAi patents, they will probably carry some weight for the use of single-stranded RNAi molecules and ISIS is indeed pursuing such single-strand RNAi molecules for therapeutic purposes. Importantly, however, their utility in an in vivo setting still remains to be demonstrated.

No comments:

By Dirk Haussecker. All rights reserved.

Disclaimer: This blog is not intended for distribution to or use by any person or entity who is a citizen or resident of, or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject the author or any of his collaborators and contributors to any registration or licensing requirement within such jurisdiction. This blog expresses only my opinions, they may be flawed and are for entertainment purposes only. Opinions expressed are a direct result of information which may or may not be accurate, and I do not assume any responsibility for material errors or to provide updates should circumstances change. Opinions expressed in this blog may have been disseminated before to others. This blog should not be taken as investment, legal or tax advice. The investments referred to herein may not be suitable for you. Investments particularly in the field of RNAi Therapeutics and biotechnology carry a high risk of total loss. You, the reader must make your own investment decisions in consultation with your professional advisors in light of your specific circumstances. I reserve the right to buy, sell, or short any security including those that may or may not be discussed on my blog.